(Hypertension. 1996;27:774-780.)
© 1996 American Heart Association, Inc.
Articles |
From the Centre de Recherche Hôtel-Dieu de Montréal, Université de Montréal (Québec), Canada.
Correspondence to Pavel Hamet, MD, PhD, Laboratory of Molecular Pathophysiology, Centre de Recherche Hôtel-Dieu de Montréal, 3850 St. Urbain St, Montréal, Québec H2W 1T8, Canada.
| Abstract |
|---|
|
|
|---|
Key Words: muscle, smooth, vascular calcium channels cyclic AMP cytoskeleton
| Introduction |
|---|
|
|
|---|
Despite numerous data on cAMP-induced vasorelaxation, the mechanism of this phenomenon is poorly understood. The initial hypothesis on cAMP-induced decrease of Ca2+ sensitivity of myosin light-chain kinase was based on reversible phosphorylation of this enzyme from turkey gizzard smooth muscle by protein kinase A in vitro.4 This observation was subsequently confirmed in tracheal smooth muscle cells.5 However, to the best of our knowledge, there are no data on cAMP-induced phosphorylation of myosin light-chain kinase in VSMCs or on the correlation of smooth muscle relaxation and cAMP-induced phosphorylation of this enzyme in vivo. On the contrary, it has been shown that forskolin-induced relaxation of carotid arteries is not associated with altered Ca2+ sensitivity of myosin light-chain kinase.6
It may be assumed that apart from the modulation of activity of Ca2+-sensitive enzymes involved in excitation-contraction coupling, cAMP affects intracellular Ca2+ concentration. Indeed, in cardiac muscle, ß-adrenergic activation of cAMP signaling is accompanied by phosphorylation of the 22-kD protein phospholamban, which leads to severalfold activation of the sarcoplasmic reticulum Ca2+ pump.7 In VSMCs, phospholamban phosphorylation occurs at the same site as in cardiac cells but is mediated predominantly by cGMP-dependent protein kinase (for more details, see Reference 8). Several types of protein kinases, in particular protein kinase A, inhibit pharmacomechanical coupling triggered by the activation of ion channel and phospholipase Ccoupled receptors.9 However, this mechanism cannot explain the inhibition of electromechanical coupling in VSMCs by cAMP.
Several years ago, Ousterhout and Sperelakis10 reported that both isoproterenol and forskolin depressed Ca2+-dependent action potential in depolarized cultured VSMCs. These results suggest that cAMP inhibits electromechanical coupling by membrane hyperpolarization and/or inactivation of VDCCs. Pharmacological studies indicate that cAMP-induced membrane hyperpolarization of VSMCs is mediated by activation of K+ channels.11 Indeed, in vascular and tracheal smooth muscles, direct evidence has been obtained by the patch-clamp technique of membrane-delimited Gs proteinmediated and cytoplasmic protein kinase Amediated pathways of ß-adrenergic receptor coupling with Ca2+-activated K+ channels.12 13 14
In contrast to K+ channels, data on the modulation of VDCCs
in VSMCs by cAMP are contradictory. Thus, dialysis with cAMP solutions
had no effect on Ca2+ current in VSMCs from the rabbit
saphenous artery15 and rat portal vein.16
Benham and Tsien17 reported a threefold increase of
DHP-sensitive long-lasting (L-type) Ca2+ current in
smooth muscle cells from the rabbit ear artery treated with
norepinephrine. However, this effect was not mediated via
known subtypes of ß- or
-adrenergic receptors.17
Ishikawa and coworkers18 reported that low concentrations
of intracellular cAMP produce modest increases in whole-cell L-type
Ca2+ channel current, whereas higher cAMP concentrations
result in strong inhibition of L-type channel activity in VSMCs from
the rabbit portal vein. Membrane-permeable cAMP analogues slightly
inhibit slow, inward, long-lasting (L-type) Ca2+
channels in VSMCs isolated from the rat tail artery19 and
in cultured cells from the rabbit aorta.20 Sustained
inhibition of L-type Ca2+ was shown in freshly isolated
smooth muscle cells from the rabbit portal vein treated with forskolin
and 8-bromo-cAMP.21 In the A7r5 cell line derived from
rat embryonic smooth muscle22 and in VSMCs from the
porcine coronary artery,23 forskolin increases
L-type VDCC-mediated Ca2+ current. In contrast, Lorenz and
coworkers24 demonstrated that both cAMP analogues and
forskolin inhibit L-type VDCCs in A7r5 cells.
These contradictory results on the regulation of VDCCs by cAMP signaling are probably caused by difficulties in obtaining satisfactory whole-cell voltage-clamp recordings from small myocytes and by rapid rundown of VDCC activity. Furthermore, enzymatic digestion in Ca2+-free medium during VSMC preparation can leave dispersed or primary cultured cells with drastically altered calcium homeostasis and membrane-bound protein function.24 To overcome these problems, we studied the regulation of Ca2+ inward fluxes in long-term cultured VSMCs by radioisotope methods. We report here that DHP-sensitive VD 45Ca influx in VSMCs from the rat aorta is inhibited by activators of cAMP signaling. Our results suggest that this regulatory pathway is mediated by activation of protein kinase A and cytoskeleton rearrangement.
| Methods |
|---|
|
|
|---|
45Ca influx was measured essentially as described earlier,29 with changes in composition of the incubation media. Confluent, quiescent cultures of VSMCs (in 24-well plates) were washed twice at room temperature with 2-mL aliquots of medium A containing 150 mmol/L NaCl and 10 mmol/L HEPES-Tris (pH 7.4). One milliliter of medium B (in mmol/L: NaCl 140, KCl 5, MgCl2 1, CaCl2 1, glucose 5, HEPES-Tris 20, pH 7.4) was added to each well. After 30 minutes of preincubation at 37°C, the medium was replaced by 0.25 mL of medium B containing 0.2 mmol/L CaCl2, and the cells were incubated for a further 10 to 20 minutes at 37°C. Where appropriate, the preincubation medium contained different compounds, as indicated in the figure and table legends. Thereafter, each well was supplemented with 0.25 mL of prewarmed (37°C) low-potassium or high-potassium medium containing 5 mmol/L KCl and 140 mmol/L NaCl, respectively (final concentration of K+ and Na+, 5 and 140 mmol/L, respectively) or 125 mmol/L KCl and 20 mmol/L NaCl (final concentration of K+ and Na+, 65 and 80 mmol/L, respectively) with 2 to 4 µCi/mL 45CaCl2. The osmolality of these media was decreased by reduction of the NaCl concentration or increased by the addition of sucrose. Previously, it was shown that under these conditions, the kinetics of 45Ca uptake by VSMCs is linear up to 10 minutes.29 To estimate the rate of unidirectional inward Ca2+ fluxes, the time of incubation with the isotope was limited to 5 minutes. Incubation was terminated by the addition of 2.5 mL ice-cold solution (medium C) containing 100 mmol/L MgCl2 and 10 mmol/L HEPES-Tris (pH 7.4). The dishes were transferred onto ice, and the cells were washed 5 times with 2.5 mL of ice-cold medium C. The cells were lysed with 1 mL of 4 mmol/L EDTA/1% sodium dodecyl sulfate, and radioactivity was quantified by liquid scintillation counting. 45Ca influx was calculated as A/an, where A is radioactivity in the cell lysate (cpm), a is specific radioactivity of the incubation medium (cpm/pmol), and n is the protein content per well (in micrograms). VD (depolarization-induced) Ca2+ influx was determined as the difference between the rate of 45Ca uptake in high- and low-potassium media. The volume of intracellular water in VSMCs was determined as [14C]urea available space.30
Chemicals
45CaCl2 was obtained from
Amersham Inc;
isoproterenol bitartrate, cytochalasin B, vinblastine,
nifedipine, and nicardipine were purchased
from Sigma; forskolin, cholera toxin, pertussis toxin, and H-89
(N-[2-([3-(40
bromophenyl)-2-propenyl]-lamino)ethyl]-5-isoquinolinesulfonamide)
were procured from Calbiochem Novabiochem Corp; D-glucose,
salts, and buffers were from Sigma, Gibco, and Anachemia,
respectively.
| Results |
|---|
|
|
|---|
|
Dose Dependence of 45Ca Uptake on Nicardipine and
Nifedipine in Low- and High-Potassium Media
Increased nicardipine and
nifedipine
concentrations from 10-9 to
10-6 mol/L did not significantly modify
45Ca uptake by VSMCs under basal (low-potassium medium)
conditions (data not shown). Both DHP derivatives completely blocked
depolarization-induced 45Ca uptake in a
concentration-dependent manner with a Ki of
3 and 10 nmol/L for nifedipine and
nicardipine, respectively (Fig 2
).
|
Effect of cAMP Signaling System Modulators
Activators of
ß-adrenergic receptors,
adenylate cyclase, and Gs proteins
(isoproterenol, forskolin, and cholera toxin, respectively) increased
cAMP content in VSMCs by 50- to 100-fold (Table 1A
). These
compounds did not affect basal 45Ca influx and decreased
depolarization-induced 45Ca uptake by 50% to 70%.
Neither basal nor depolarization-induced 45Ca was
sensitive to pertussis toxin, an inhibitor of
Gi proteins. Nicardipine did not significantly modify the
effect of isoproterenol on cAMP content but completely abolished
cAMP-induced inhibition of 45Ca uptake in
high-potassium medium (Table 1A
).
Effect of Protein Kinase A Inhibitor
H-89 is known to be a
powerful and selective inhibitor
of cAMP-dependent protein kinase. Thus, in cell-free systems and at
micromolar ATP concentrations, half-maximal inhibition of protein
kinase A, protein kinase G, and protein kinase C activity by H-89 was
observed at 0.05, 0.5, and 30 µmol/L, respectively.31
Due to the high intracellular ATP concentration and limited
permeability across plasma membrane, this compound inhibits protein
kinase A activity in intact cells with an ED50 of 5 to 10
µmol/L.31 As seen in Fig 3
,
simultaneous addition of 10 µmol/L H-89 with
45Ca did not modify basal 45Ca uptake but
completely abolished the increment of 45Ca uptake in
high-potassium medium. These results demonstrate that at the same
concentration range as used for inhibition of protein kinase A activity
in vivo, H-89 completely suppressed VD Ca2+ transport in
VSMCs, probably because of the direct interaction with L-type
Ca2+ channels. To overcome this problem, we treated VSMCs
with 10 µmol/L H-89, washed the cells with BSA-containing medium to
remove extracellular H-89, and then measured 45Ca uptake in
H-89free medium. As seen in Fig 4b
, H-89 did not
modify depolarization-induced 45Ca uptake under this
protocol but abolished its regulation by forskolin. It is important to
mention that neither basal nor forskolin-induced cAMP
production was altered in H-89treated VSMCs (Fig 4a
).
|
|
Effect of Cytoskeleton Assembly Modulators
It is known that
activation of cAMP signaling in VSMCs is
accompanied by cell shape transition32 33 and
cytoskeleton
reorganization.34 We therefore compared the effects of
modulators of cytoskeleton assembly and cell volume on 45Ca
uptake by VSMCs. As seen in Table 1B
, cytochalasin B and
vinblastine
decreased depolarization-induced 45Ca uptake in BN.lx
VSMCs by 70% and 45%, respectively. It should be underscored,
however, that the effects of these cytoskeleton modulators on
Ca2+ transport in VSMCs were probably mediated by distinct
mechanisms. Indeed, cytochalasin B, an inhibitor of actin
polymerization in microfilament bundles, did not modify basal
45Ca uptake and decreased it by 35% in high-potassium
medium. In contrast to cytochalasin B, vinblastine, a
microtubule-disrupting compound, increased basal 45Ca
uptake by 60% but did not affect it in high-potassium medium.
Neither cytochalasin B nor vinblastine modified forskolin-induced
cAMP production. However, in VSMCs treated with these
compounds, forskolin did not lead to further decreases of
depolarization-induced Ca2+ influx (Table 1B
).
Effect of Cell Volume
Table 2
shows that
treatment of VSMCs with forskolin
reduced VSMC volume by 12% to 15%, which is in accordance with data
obtained on VSMCs treated with isoproterenol.33 The same
cell volume decrease (from 3.1 to 2.4 µL/mg protein) induced by
hyperosmotic shrinkage did not alter depolarization-induced
45Ca uptake by VSMCs (Fig 5
, curve 3). Under
the same conditions of cell shrinkage, we did not observe any changes
of forskolin-induced cAMP production and its regulation of
VD 45Ca uptake (Table 2
). A further decrease of VSMC
volume
from 2.4 to 1.6 µL/mg protein completely blocked
depolarization-induced 45Ca uptake (Fig 5
).
|
|
| Discussion |
|---|
|
|
|---|
|
Recently, it was reported that cAMP analogues inhibit L-type
Ca2+ current in rat osteoblastic cells,36
indicating that this mechanism of VDCC regulation is not limited to
VSMCs. On the other hand, it is well documented that in most
electrically excitable tissues (cardiomyocytes, skeletal
fibers, neurons), cAMP enhances L-type VDCCs (see References 37 through
39 for review). ß-Adrenergic regulation of ion channels can be
mediated by cAMP-independent and cAMP-dependent pathways. The
cAMP-independent membrane-delimited pathway is triggered by direct
interaction of ion channels with the activated
-subunit
of Gs proteins,40 whereas the cAMP-dependent
cytoplasmic pathway probably involves the activation of protein kinase
A.41 In our study, we did not find significant differences
between isoproterenol, forskolin, and cholera toxin in the inhibition
of VD Ca2+ influx in VSMCs (Table 1
). In the
presence of
forskolin, isoproterenol did not lead to a further reduction of VD
45Ca uptake (data not shown). Inhibition of VD
Ca2+ influx by forskolin (Fig 4
) and
isoproterenol (data
not shown) was completely abolished by pretreatment of VSMCs with H-89,
an inhibitor of protein kinase A. These results are in
accordance with data on partial inhibition of L-type channels in VSMCs
from rabbit portal vein by a catalytic subunit of protein kinase
A21 and indicate that ß-adrenergicinduced
inhibition of L-type VDCCs in VSMCs is mediated by the cytoplasmic
protein kinase A pathway.
Protein kinase Ainduced inhibition of VD Ca2+ influx
in
VSMCs may be caused by phosphorylation of (1) the
L-type channel itself and, in particular, its
1-subunit
possessing several potential phosphorylation sites or
(2) a contiguous regulatory type of protein(s). The first hypothesis
seems unlikely. Indeed, despite opposite effects of cAMP on L-type
VDCCs in VSMCs and cardiomyocytes, cDNA sequencing has
predicted high homology of their
1-subunits.42 Moreover, it has been shown
that cAMP does not affect Ca2+ channel currents in
Xenopus oocytes resulting from expression of the
1-subunit of VSMC VDCCs alone.43 Apart from
the
1-subunit, a potential
phosphorylation site for protein kinase A has also been
demonstrated in the ß-subunit of skeletal muscle L-type VDCCs
(see Reference 38 for review). Coexpression of the VSMC
1-subunit with the skeletal muscle ß-subunit led
to twofold activation of VD Ca2+ current in
Xenopus oocytes. It should be underscored, however,
that the same results were obtained with coexpressed
1-subunit from cardiac myocytes.43
Searching for candidate proteins that could be involved in the
inhibition of VD Ca2+ influx in VSMCs, we focused on
cAMP-induced VSMC shape transition and cytoskeleton reorganization
first reported by Smith32 and later confirmed in other
laboratories.33 34 Data obtained in the present study
show that reorganization of the cytoskeleton network with cytochalasin
B and vinblastine inhibits VD 45Ca uptake in VSMCs and
abolishes its regulation by cAMP signaling (Table 1B
). These
results
demonstrate that intact cytoskeleton is necessary for proper
Ca2+ channel functions and suggest that cAMP-induced
cytoskeleton reorganization is involved in the inhibition of L-type
channel activity. Here, it is important to underscore that
cytoskeleton-mediated regulation of plasma membrane ion currents is
not limited by L-type Ca2+ channels. Thus, it was recently
shown that cytochalasin D reduces whole-cell peak Na+
current in rat and rabbit ventricular cardiac
myocytes44 and prevents activation of cystic fibrosis
transmembrane conductance regulator-mediated Cl-
conductance in mouse mammary adrenocarcinoma by cAMP
analogues.45
Apart from shape transition, cAMP induces a decrease of VSMC volume by
12% to 15% (Table 2
). Keeping in mind numerous data on the
volume-dependent regulation of ion transport,46 we
assumed that cAMP-induced inhibition of VD Ca2+ influx
could be mediated by VSMC shrinkage. However, results obtained with
hyperosmotically shrunken VSMCs contradict this assumption. Indeed, as
seen in Fig 5
, moderate hyperosmotic shrinkage did not modify
VD
45Ca uptake by VSMCs.
In conclusion, the present study demonstrates that in contrast to skeletal and cardiac myocytes, cAMP inhibits VD DHP-sensitive Ca2+ influx in cultured smooth muscle cells from the rat aorta. It may be assumed that this signaling pathway plays a key role in vasorelaxation triggered by adenylate cyclasecoupled receptors. The inhibitory effect of cAMP on L-type Ca2+ channels deserves further investigation to determine the mechanism of its interrelation with protein phosphorylation and cytoskeleton network rearrangement.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2. Messerli FH, Kuchel O, Hamet P, Tolis G, Guthrie GP Jr, Fraysse J, Nowaczynski W, Genest J. Plasma cyclic adenosine 3':5'-monophosphate response to isoproterenol and glucagon in hyperkinetic borderline (labile) hypertension. Circ Res. 1976;38(suppl 2):II-42-II-47.
3. Hamet P, Orlov SN, Tremblay J. Intracellular signalling mechanisms in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management (Vol 1). 2nd ed. New York, NY: Raven Press; 1995:575-607.
4.
Adelstein RS, Conti MA, Hathaway DR.
Phosphorylation of smooth muscle myosin light chain
kinase by the catalytic subunit of adenosine-3'
5'-monophosphate dependent protein kinase. J
Biol Chem. 1978;253:8347-8350.
5.
Stull JT, Hsu LC, Tansey MG, Kamm KE. Myosin
light chain kinase phosphorylation in tracheal smooth
muscle. J Biol Chem. 1990;265:16683-16690.
6.
McDaniel NL, Rembold CM, Richard HM, Murphy RA.
Cyclic AMP relaxes swine arterial smooth muscle
predominantly by decreasing cell Ca2+
concentration. J Physiol. 1991;439:147-160.
7.
Lindemann JP, Jones LR, Hathaway DR, Henry BG,
Watanabe AM. ß-Adrenergic stimulation of phospholamban
phosphorylation and Ca2+-ATPase activity in
guinea pig ventricles. J Biol Chem. 1993;258:464-471.
8.
O'Donnell ME, Owen NE. Regulation of ion pump
and carriers in vascular smooth muscle. Physiol Rev. 1994;74:683-721.
9.
Chen XL, Rembold CM. Cyclic
nucleotide-dependent regulation of Mn2+
influx, [Ca2+]i, and
arterial smooth muscle relaxation. Am J
Physiol. 1992;263:C468-C473.
10. Ousterhout JM, Sperelakis N. Cyclic nucleotides depress action potentials in cultured aortic smooth muscle cells. Eur J Pharmacol. 1987;144:7-14. [Medline] [Order article via Infotrieve]
11.
Stekiel WJ, Contney SJ, Rusch NJ. Altered
ß-receptor control of in situ membrane
potential in hypertensive rats. Hypertension. 1993;21:1005-1009.
12.
Sadoshima TI, Akaike N, Kanaide N, Nakamura M.
Cyclic AMP modulates Ca-activated K channel in cultured
smooth muscle cells of rat aortas. Am J Physiol. 1988;255:H754-H759.
13.
Kume H, Graziano MP, Kotlikoff MI. Stimulatory
and inhibitory regulation of calcium-activated
potassium channels by guanosine-nucleotide-binding
proteins. Proc Natl Acad Sci U S A. 1992;89:11051-11055.
14.
Scornik FS, Codina J, Birnbaumer L, Toro L.
Modulation of coronary smooth muscle KCa channels
by Gsa independent of phosphorylation by
protein kinase A. Am J Physiol. 1993;265:H1460-H1465.
15.
Okie M, Kitamura K, Kuriyama H. Histamine
H2-receptor activation augments voltage-dependent
Ca2+ current via GTP hydrolysis in rabbit saphenous
artery. J Physiol. 1992;448:133-152.
16.
Loirand G, Pacaud P, Mironneau C, Mironneau J.
GTP-binding protein mediates noradrenaline effects on
calcium and chloride currents in rat portal vein myocytes.
J Physiol. 1990;428:517-529.
17.
Benham CD, Tsien RW. Noradrenaline
modulation of calcium channels in single smooth muscle cells from
rabbit ear aorta. J Physiol. 1988;404:767-788.
18.
Ishikawa T, Hume JR, Keef KD. Regulation of
Ca2+ channels by cAMP and cGMP in vascular smooth muscle
cells. Circ Res. 1993;73:1128-1137.
19.
Wang R, Karpinski E, Pang PKT. Parathyroid
hormone selectively inhibits L-type calcium channels in single vascular
smooth muscle cells of the rat. J Physiol. 1991;441:325-346.
20. Bkaily G, Yamamoto T, Peyrow M, Sculptoreanu A, Jacques D, Sperelakis N. Macroscopic Ca2+ and K+ currents in single cardiac and aortic cells. Mol Cell Biol. 1988;80:59-72.
21. Xiong Z, Sperelakis N, Fenoglio-Preiser C. Regulation of L-type calcium channels by cyclic nucleotides and phosphorylation in smooth muscle cells from rabbit portal vein. J Vasc Res. 1994;31:271-279. [Medline] [Order article via Infotrieve]
22. Marks TN, Dubyah GR, Jones SW. Calcium currents in the A7r5 smooth muscle-derived cell line. Pflugers Arch. 1990;417:433-439. [Medline] [Order article via Infotrieve]
23. Fukumitsu T, Hayaschi H, Tokuno H, Tomita T. Increase of calcium current by ß-adrenoceptor agonists in single smooth muscle cells isolated from porcine coronary artery. Br J Pharmacol. 1990;100:593-599. [Medline] [Order article via Infotrieve]
24.
Lorenz JN, Bielefeld D, Sperelakis N. Regulation
of calcium channel current in A7r5 vascular smooth muscle cells by
cyclic nucleotides. Am J Physiol. 1994;266:C1656-C1663.
25. Franks DJ, Plamondon J, Hamet P. An increase in adenylate cyclase activity precedes DNA synthesis in cultured vascular smooth muscle cells. J Cell Physiol. 1984;119:41-45. [Medline] [Order article via Infotrieve]
26. Hadrava V, Tremblay J, Hamet P. Effect of cell density and growth factors on proliferation of vascular smooth muscle cells from SHR. Proc. Sixth Annual Symposium on SHR and Related Studies. Iowa City, Iowa, May 22-24, 1989. Abstract.
27. Hartee EI. Determination of protein content: a modification of the Lowry method that gives a linear photometric response. Anal Biochem. 1972;48:422-427.[Medline] [Order article via Infotrieve]
28.
Hamet P, Pang SC, Tremblay J. Atrial
natriuretic factor-induced egression of cyclic
guanosine 3':5'-monophosphate in cultured vascular smooth muscle
and
endothelial cells. J Biol
Chem. 1989;264:12364-12369.
29.
Orlov S, Resink TJ, Bernhardt J, Ferracin F,
Bühler FR. Vascular smooth muscle cell calcium fluxes:
regulation by angiotensin II and lipoproteins.
Hypertension. 1993;21:195-203.
30. Orlov SN, Resink TJ, Bernhardt J, Bühler FR. Volume-dependent regulation of sodium and potassium fluxes in cultured vascular smooth muscle cells: dependence on medium osmolality and regulation by signalling systems. J Membr Biol. 1992;129:199-210. [Medline] [Order article via Infotrieve]
31.
Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K,
Inoue T, Naito K, Toshioka T, Hidaha H. Inhibition of
forskolin-induced neurite outgrowth and protein
phosphorylation by a newly synthesized selective
inhibitor of cyclic AMP-dependent protein kinase, compound
H-89. J Biol Chem. 1990;265:5267-5272.
32. Smith JB. Beta-adrenergic stimulation inhibits calcium efflux and alters the morphology of cultured arterial muscle cells. J Cell Physiol. 1984;121:375-382. [Medline] [Order article via Infotrieve]
33. Orlov SN, Tremblay J, Hamet P. Altered ß-adrenergic regulation of Na+, K+ cotransport in cultured smooth muscle cells from the aorta of spontaneously hypertensive rats: role of the cytoskeleton network. Am J Hypertens. 1995;8:739-747.[Medline] [Order article via Infotrieve]
34. Chaldakov GN, Nabika T, Nara T, Yamori Y. Cyclic AMP- and cytochalasin B-induced arborization in cultured aortic smooth muscle cells: its cytopharmacological characterization. Cell Tissue Res. 1989;255:432-442.
35.
Kuga T, Sadoshima J, Tomoike H, Kanaide H, Akaike N,
Nakamura M. Action of Ca2+ antagonists
on two types of Ca2+ channels in rat aorta smooth muscle
cells in primary culture. Circ Res. 1990;67:469-480.
36. Fritsch J, Chesnoy-Marchais D. Dual modulation of the L-type calcium current of rat osteoblastic cells by parathyroid hormone: opposite effects of protein kinase C and cyclic nucleotides. Cell Signal. 1994;6:645-655. [Medline] [Order article via Infotrieve]
37.
Kostyuk PG. Intracellular perfusion of nerve
cells and its effects on membrane current. Physiol
Rev. 1984;64:435-454.
38.
McDonald TF, Pelzer S, Trautwein W, Pelzer D.
Regulation and modulation of calcium channels in cardiac, skeletal, and
smooth muscle cells. Physiol Rev. 1994;74:365-507.
39. Sperelakis N, Tohse N, Ohya Y, Masuda H. Cyclic GMP regulation of calcium channels in cardiac and vascular smooth muscle cells. Adv Pharmacol. 1994;26:217-252.
40. Birnbaumer L, Abramowitz J, Brown AM. Receptor-effector coupling by G-proteins. Biochim Biophys Acta. 1990;1031:185-224.
41. Levitan IB. Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol. 1994;56:193-212. [Medline] [Order article via Infotrieve]
42. Hullin R, Biel M, Flockerzi V, Hofmann F. Tissue specific expression of calcium channels. Trends Cardiovasc Med. 1993;3:45-53.
43. Klockner U, Itagaki K, Bodi I, Schwartz A. ß-Subunit expression is required for cAMP-dependent increase of cloned cardiac and vascular calcium channel currents. Pflugers Arch. 1992;420:413-415. [Medline] [Order article via Infotrieve]
44.
Udrovinas AI, Shander GS, Makielski JC.
Cytoskeleton modulates gating of voltage-dependent sodium channels
in heart. Am J Physiol. 1995;269:H203-H214.
45.
Prat GA, Xiao YF, Ausiello DA, Cantiello H.
cAMP-independent regulation of CFTR by the actin cytoskeleton.
Am J Physiol. 1995;268:C1552-C1561.
46.
Hoffman EK, Simonsen LO. Membrane mechanisms in
volume and pH regulation in vertebrate cells. Physiol
Rev. 1989;69:315-382.
This article has been cited by other articles:
![]() |
M Hennenberg, J Trebicka, T Sauerbruch, and J Heller Mechanisms of extrahepatic vasodilation in portal hypertension Gut, September 1, 2008; 57(9): 1300 - 1314. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Zhang, Y. Shirasawa, X. Chen, H. Yu, and J. N. Benoit Impaired agonist-dependent myosin phosphorylation and decreased RhoA in rat portal hypertensive mesenteric vasculature Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G603 - G608. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Gosmanov, Z. Fan, X. Mi, E. G. Schneider, and D. B. Thomason ATP-sensitive potassium channels mediate hyperosmotic stimulation of NKCC in slow-twitch muscle Am J Physiol Cell Physiol, March 1, 2004; 286(3): C586 - C595. [Abstract] [Full Text] |
||||
![]() |
S. Taurin, N. O Dulin, D. Pchejetski, R. Grygorczyk, J. Tremblay, P. Hamet, and S. N Orlov c-Fos expression in ouabain-treated vascular smooth muscle cells from rat aorta: evidence for an intracellular-sodium-mediated, calcium-independent mechanism J. Physiol., September 15, 2002; 543(3): 835 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. PURDY and W. J. ARENDSHORST Iloprost Inhibits Inositol-1,4,5-Trisphosphate-Mediated Calcium Mobilization Stimulated by Angiotensin II in Cultured Preglomerular Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2001; 12(1): 19 - 28. [Abstract] [Full Text] |
||||
![]() |
K. L. Dodge, D. W. Carr, and B. M. Sanborn Protein Kinase A Anchoring to the Myometrial Plasma Membrane Is Required for Cyclic Adenosine 3',5'-Monophosphate Regulation of Phosphatidylinositide Turnover Endocrinology, November 1, 1999; 140(11): 5165 - 5170. [Abstract] [Full Text] |
||||
![]() |
M. S. Taylor and J. N. Benoit Effect of milrinone on small mesenteric artery vasoconstriction: role of K+ channels Am J Physiol Gastrointest Liver Physiol, July 1, 1999; 277(1): G69 - G78. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. STOCKAND and S. C. SANSOM Glomerular Mesangial Cells: Electrophysiology and Regulation of Contraction Physiol Rev, July 1, 1998; 78(3): 723 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uhlig, R. L. Featherstone, H.-D. Held, R. Nüsing, C. Schudt, and A. Wendel Attenuation by Phosphodiesterase Inhibitors of Lipopolysaccharide-Induced Thromboxane Release and Bronchoconstriction in Rat Lungs J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1453 - 1459. [Abstract] [Full Text] |
||||
![]() |
N. O. Dulin, J. Niu, D. D. Browning, R. D. Ye, and T. Voyno-Yasenetskaya Cyclic AMP-independent Activation of Protein Kinase A by Vasoactive Peptides J. Biol. Chem., June 8, 2001; 276(24): 20827 - 20830. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |